[HTML][HTML] Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice
LM Pérez-Belmonte, J Sanz-Cánovas… - Frontiers in …, 2022 - frontiersin.org
Background The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.
LM Pérez-Belmonte, J Sanz-Cánovas… - Frontiers in …, 2022 - europepmc.org
Background The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
LM Pérez-Belmonte, J Sanz-Cánovas… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …
[PDF][PDF] Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
LM Perez-Belmonte, J Sanz-Canovas… - Front. Endocrinol. 13 …, 2022 - academia.edu
Background: The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
LM Perez-Belmonte, J Sanz-Canovas… - Frontiers in …, 2022 - jglobal.jst.go.jp
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2
Diabetes and Chronic Heart Failure in Real-World Clinical Practice | Article Information | J-GLOBAL …
Diabetes and Chronic Heart Failure in Real-World Clinical Practice | Article Information | J-GLOBAL …
[HTML][HTML] Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
LM Pérez-Belmonte, J Sanz-Cánovas… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Background The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …
[PDF][PDF] Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
LM Perez-Belmonte, J Sanz-Canovas… - Front. Endocrinol. 13 …, 2022 - academia.edu
Background: The impact of glucagon-like peptide-1 receptor agonists on patients with heart
failure has not been fully described. Our main objective was to evaluate the safety and …
failure has not been fully described. Our main objective was to evaluate the safety and …